Jill Feldman

Deadline is approaching!

Are you doing research in #EGFR+ #lungcancer — OR mentoring someone who is — submit an abstract to the EGFR Resisters Research Summit
Concepts welcome
Deadline-August 8.
Submit Abstract - ceconcepts.com/egfr-summit

#NSCLC #ThoracicOnc #HOFellows #EGFRResisters
#OncoAlert

Heading to #ASCO25 this year? Be sure to join us for the first ever #ASPIRE Community of Practice on Friday, May 30th: 4-6pm CST in E253cd. We have a great agenda and opportunity to connect with other #irAE aficionados @ascocancer.bsky.social @funchainmd.bsky.social www.asco.org/annual-meeti...

a baby is sitting on a couch and making a face ALT: a baby is sitting on a couch and making a face

I sometimes feel like people are sick and tired of me being sick and tired

Episode 30: Fatigue and Cancer- Symptom of cancer or a sign of a toxicity? Podcast Episode · Checkpoint NOW · 05/09/2025 · 42m

Sick and tired of being sick and tired? Thanks @funchainmd.bsky.social & Afreen Shariff for the chance to discuss cancer-related fatigue @ascocancer.bsky.social @americancancersoc.bsky.social @pallonccop.bsky.social @oncoalert.bsky.social @aspire-cop.bsky.social podcasts.apple.com/us/podcast/e...

Welcome #pallonc #supponc folks to the official Blue Sky account for ASCO supported #PallOncCoP. Please follow for official Zoom meeting events, in-person conference meet ups like pic #ASCO24 and sharing the latest science in comfort and cure.

I will co-chair with Prof Maryam Lustberg on June 26th AM
"Workshop 1: Partnering with patients in managing chronic toxicities of cancer and its treatment."
bringing together multidisciplinary professionals, cancer patients, survivors and carers to compare best practices for management toxicities.

My Guiding Compass in Advocacy:

Speak up, but do it with respect.
Challenge, but do it with understanding.
And always push forward with purpose — Real change happens through conversation, not confrontation.

I was 28 when my mom died, but her profound wisdom always guides me 💙

The Power of Unity: Why the Lung Cancer Genetics Study Matters The Lung Cancer Genetics Study, a collaboration between lung cancer advocacy organizations, aims to explore the genetics of lung cancer

Jill Feldman wrote a powerful article for @curetoday.bsky.social about the #LungCancerGeneticsStudy – a collaboration between nearly two dozen #LungCancer organizations and 23andme to uncover the genetic risks of lung cancer. Read it at: www.curetoday.com/view/the-pow...

@jillfeldman4.bsky.social

ASCO has a palliative care community of practice in which a patient advocate pillar was organized with @jillfeldman4.bsky.social, Ameish, and I as members. I have served since September 2023 as the lead and will hand over the role later this year.

Please email pallonccop@gmail.com to be added to the listserv.

Helping Health Professionals Reduce Lung Cancer Stigma Researchers have developed a training program to help health providers reduce lung cancer stigma and have launched a clinical trial to test the training.

Words Matter isn't just a catchphrase. It is a simple yet profound truth when talking about #lungcancer

Thank you, Drs Jamie Ostroff & Smita Banerjee, for your efforts to develop a training that offers strategies for empathic communication to ⬇️ stigma bit.ly/4gWH1Si

#LCSM #EndStigmaNow

THIS!

Easy-to-use, available regimen significantly ⬇️ frequency & severity of Grade 2+ AEs SOC for patients on first-line Ami/Lazer.

Like “Stay ahead of the pain,” “Stay ahead of the side effects” boosts QOL & ⬇️ dose interrupt/discontine—a win for everyone. 👏
#LCSM #SuppOnc
bit.ly/4jiKwUz

What a pleasure it was to meet Donghoon Shin! His passion and desire to learn from patient advocates was genuine and impressive. The future of #lungcancer research is bright😎
#LCSM #EGFR

ICYMI
"We must rethink how we define progress in oncology"
#Oncosky #Cansky #Pallonc

More people surviving lung cancer, but work remains in screening and biomarker testing The American Lung Association has released its annual "State of Lung Cancer" report.

“The most common cause of death from cancer is from lung cancer…yet just 16% of eligible people get screened for lung cancer, far lower than screening rates for colorectal or breast cancer. “ #medsky ktul.com/news/nation-...

The trade-off between accelerated cancer drug approvals and patient preferences Cancer care stands at a critical juncture where the urgency of rapid drug approvals must be balanced against the need for enduring patient-centric benefits. Robin Forrest and colleagues1 conducted a d...

Innovation shouldn't come at the expense of patient-centered care!
Great article about prioritizing what matters to patients (QOL/OS/⬇️ burdens). It underscores palliative care being viewed as essential, not ancillary.
We must rethink how we define progress in #oncology
#pallonc #LCSM
bit.ly/3OJQuQB

great idea!

Lung cancer—a one-way ticket The physician’s duty is not to stave off death or return patients to their old lives, but to take into our arms a patient and family whose lives have disin

It was an honor to co-author this article
bit.ly/40WN9Vr
It emphasizes the profound impact of a #lungcancer dx, highlighting the multifaceted challenges patients/families face.
It's time to transform the “one-way ticket” into an experience of hope, support & compassionate care.
#LCAM #LCSM

Systemic Therapy for Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update | Journal of Clinical Oncology ASCO Rapid Recommendation Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing data. The rapid updates are supported by an e...

Working on the #ASCO #SCLC guidelines, published in 2023, was disheartening, but working on the rapid update (based on #ASCO24 data) left me emotional.
This update represents hope & progress for patients who have waited far too long. ascopubs.org/doi/10.1200/...
#LCSM

Looking forward to it!

Today's the day! Our last PallOncCoP meeting of 2024! Don't miss it. Not too late to DM📨 for Zoom 🔗. Always stay in the know by sending your prof email to pallonccop@gmail.com to be added to our listserv.

@darcyburbage.bsky.social
@tingtingzhang.bsky.social
@jillfeldman4.bsky.social

The #lungcancer screening team at RushCancer Center
has had a 50% uptake in screening for the 3rd year! Congratulations to Annie and the team, and thank you for your tireless efforts to raise awareness about lung cancer screening!
#LCSM #LCAM #EarlyDetectionSavesLives

FDA Involvement in Dose Optimization Through Project Optimus Drives a Patient-Focused Oncology Pharmacology Career: With D. Ross Camidge, MD, PhD; and Jeanne Fourie Zirkelbach, PhD Drs Camidge and Zirkelbach discuss Zirkelbach's first pharmacokinetics forays and her involvement with reforming dose optimization in drug development.

Great episode Dr Ross Camidge's podcast #HowThisIsBuildingMe with pharmacologist Dr. Zirkelbach (FDA Onc) on drug dev & her focus on #PROs for best outcomes w/fewest AEs

I always learn, but still have questions about #ProjectOptimus
bit.ly/48RlOpz
#LCAM #LCSM #TheRightDose
@itsnotpink.bsky.social

📢 The @ASCO released updated living guidelines for treating stage IV #NSCLC with driver alterations! ascopubs.org/doi/10.1200/....

This is no easy feat, but it was an honor to work alongside exceptional experts dedicated to providing the most up-to-date, evidence-based guidance.
#LCSM #LCAM

Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.2 | Journal of Clinical Oncology Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedul...

The "Living" #ASCOGuidelines embraces change and supports #OncSky clinicians and people LIVING with mutation-driven lung cancer in making informed treatment choices. Congrats to the expert panel! ascopubs.org/doi/full/10.... @jillfeldman4.bsky.social #LCSM

Voting in the ASCO Election is open now until December 3! Meet the candidates for the Board of Directors – Undesignated Member seat.

Learn more about each candidate, determine your voting eligibility, and make your voice heard at brnw.ch/21wOzu3

"the new generation of cancer survivor [is] younger, less financially secure, and still having to navigate life after treatment, from dating to career, sex and child rearing"

So glad that #AYAcsm #survonc #financialToxicity & #MBC issues are getting time on NPR

www.npr.org/2024/11/11/n...

Let me know if you find out how to spread the word. I would love nothing more than to leave X!

I made a #LCSM list, small but growing! Not sure how to make it public? bsky.app/profile/did:...

@jackwestmd.bsky.social @stephenvliu.bsky.social @pateloncology.bsky.social @tlblase.bsky.social @devikadasmd.bsky.social @jia-luo.bsky.social @garthnicholas.bsky.social